These preliminary results are based on management’s initial analysis of operations for the quarter ended March 29, 2025, and are subject to further internal review, potential adjustments and review by ...

compared to $12.5 million in the prior year quarter Cyclo G6 ® product family revenue in the fourth quarter reached $3.3 million, compared to $3.0 million in the prior year quarter Sold 13,300 ...

Total product revenue for the Cyclo G6 glaucoma product family reached $3.3 million, a 9% increase year-over-year, supported by improved clarity in the U.S. glaucoma reimbursement environment.

It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight ...

It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight ...

Total revenue is expected to be between $11.8 million and $12.0 million, compared to $11.8 million in the comparable quarter of 2024 Sold approximately 13,900 Cyclo G6 probes, compared to 13,300 ...

Total product revenue from the Cyclo G6 Glaucoma product family was $3.3 million, an increase of 9% versus the fourth quarter of 2023. Retina product revenue was $7.3 million or a decrease of 3% ...

Total product revenue from the Cyclo G6 Glaucoma product family was $3.3 million, an increase of 9% versus the fourth quarter of 2023. Retina product revenue was $7.3 million or a decrease of 3% ...